665P First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation

John V. Heymach, Nuria Kotecki, Hans Prenen, Guzmán Alonso, Colin R. Lindsay, Minal Barve, Claus Thamer, Sabina Eigenbrod-Giese, Marcelo Marotti, Griet Van Lancker